Future Directions in Desmoid Tumor Research and Treatment and Clinical Practice Integration

Dr. Basu Mallick draws parallels between different gamma-secretase inhibitors and aromatase inhibitors, suggesting similar efficacy profiles with potential advantages for once-daily dosing in terms of patient compliance. Although cross-trial comparisons have limitations, varagesestat appeared to demonstrate deeper responses, though both agents show substantial efficacy.

Treatment sequencing questions remain unanswered, particularly whether patients can benefit from sequential gamma-secretase inhibitors or if cross-resistance develops within the class. The RINGSIDE patient population had not received prior nirogacestat, limiting insights into sequential treatment strategies.

Dr. Bui emphasizes the need for prospective studies addressing optimal treatment duration, currently a major unmet need in clinical practice. Questions include whether predetermined time-limited treatments followed by observation periods could be effective, or if continuous therapy remains necessary.

The development of direct beta-catenin inhibitors like FOG-001 represents an exciting alternative mechanism targeting the root cause of desmoid pathogenesis. This intravenous weekly therapy with different side effect profiles may complement existing oral options and provide alternatives for patients who don't respond to gamma-secretase inhibitors.

Outstanding research priorities include determining biomarkers for treatment selection, understanding resistance mechanisms, developing combination strategies, and addressing the subset of patients who don't respond to any current therapies. Cell line development by the Desmoid Tumor Foundation should facilitate translational research efforts.

The field has transformed dramatically compared to a decade ago, providing patients with multiple meaningful treatment options that significantly improve quality of life. Patient advocacy groups played crucial roles in advancing gamma-secretase inhibitor development, demonstrating the importance of patient engagement in research prioritization and clinical trial development